Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 196

1.

Using the Lymph2Cx assay for assessing cell-of-origin subtypes of HIV-related diffuse large B-cell lymphoma.

Baptista MJ, Tapia G, Morgades M, Muncunill J, Muñoz-Marmol AM, Montoto S, Gribben JG, Calaminici M, Martinez A, Gonzalez-Farre B, Dlouhy I, González-Barca E, Terol MJ, Miralles P, Alcoceba M, Vall-Llovera F, Briones J, Abrisqueta P, Abella E, Provencio M, García-Ballesteros C, Moraleda JM, Sancho JM, Ribera JM, Mate JL, Navarro JT.

Leuk Lymphoma. 2018 Oct 15:1-5. doi: 10.1080/10428194.2018.1512711. [Epub ahead of print] No abstract available.

PMID:
30322315
2.

A combination of hydroxytyrosol, omega-3 fatty acids and curcumin improves pain and inflammation among early stage breast cancer patients receiving adjuvant hormonal therapy: results of a pilot study.

Martínez N, Herrera M, Frías L, Provencio M, Pérez-Carrión R, Díaz V, Morse M, Crespo MC.

Clin Transl Oncol. 2018 Oct 6. doi: 10.1007/s12094-018-1950-0. [Epub ahead of print]

PMID:
30293230
3.

Lung cancer in Spanish women: The WORLD07 project.

Garrido P, Viñolas N, Isla D, Provencio M, Majem M, Artal A, Carcereny E, Garcia Campelo R, Lianes P, De La Peñas R, Felip E.

Eur J Cancer Care (Engl). 2018 Oct 2:e12941. doi: 10.1111/ecc.12941. [Epub ahead of print]

PMID:
30277293
4.

Consolidation treatment with yttrium-90 ibritumomab tiuxetan after new induction regimen in advanced stage follicular lymphoma: update results from the Spanish Lymphoma Oncology Group trial after a median follow-up of 8.5-years.

Provencio M, Franco F, Gómez-Codina J, Quero Blanco C, Llanos M, Garcia-Arroyo F, de la Cruz L, Gumá J, Delgado JR, Álvarez R, Chacón JI, Royuela A, Rueda A.

Leuk Lymphoma. 2018 Sep 20:1-4. doi: 10.1080/10428194.2018.1509322. [Epub ahead of print] No abstract available.

PMID:
30234403
5.

Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib Study.

Kim ES, Kelly K, Paz-Ares LG, Garrido P, Jalal S, Mahadevan D, Gutierrez M, Provencio M, Schaefer E, Shaheen M, Johnston EL, Turner PK, Kambhampati SRP, Beckmann R, Hossain A, John WJ, Goldman JW.

Clin Cancer Res. 2018 Aug 6. doi: 10.1158/1078-0432.CCR-18-0651. [Epub ahead of print]

PMID:
30082474
6.

Hyperprogression as a distinct outcome after immunotherapy.

Fuentes-Antrás J, Provencio M, Díaz-Rubio E.

Cancer Treat Rev. 2018 Jul 18;70:16-21. doi: 10.1016/j.ctrv.2018.07.006. [Epub ahead of print] Review.

PMID:
30053725
7.

Profiling Lung Cancer Patients Using Electronic Health Records.

Menasalvas Ruiz E, Tuñas JM, Bermejo G, Gonzalo Martín C, Rodríguez-González A, Zanin M, González de Pedro C, Méndez M, Zaretskaia O, Rey J, Parejo C, Cruz Bermudez JL, Provencio M.

J Med Syst. 2018 May 31;42(7):126. doi: 10.1007/s10916-018-0975-9.

PMID:
29855732
8.

An exploratory, large-scale study of pain and quality of life outcomes in cancer patients with moderate or severe pain, and variables predicting improvement.

Maximiano C, López I, Martín C, Zugazabeitia L, Martí-Ciriquián JL, Núñez MA, Contreras J, Herdman M, Traseira S, Provencio M.

PLoS One. 2018 Apr 3;13(4):e0193233. doi: 10.1371/journal.pone.0193233. eCollection 2018.

9.

Description and Survival of Stage I and II Lung Cancer Patients.

Pérez-Martínez O, Vidal-García I, Montero-Martínez C, Provencio M, Ruano-Ravina A.

Arch Bronconeumol. 2018 Aug;54(8):420-426. doi: 10.1016/j.arbres.2018.02.007. Epub 2018 Mar 16. English, Spanish.

10.

Long-term follow up of Hodgkin lymphoma.

Perez-Callejo D, Zurutuza L, Royuela A, Torrente M, Núñez B, Calvo V, Méndez M, Franco F, Brenes MA, Sánchez JC, Provencio M.

Oncotarget. 2018 Feb 3;9(14):11638-11645. doi: 10.18632/oncotarget.24392. eCollection 2018 Feb 20.

11.

Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.

Jurczak W, Zinzani PL, Gaidano G, Goy A, Provencio M, Nagy Z, Robak T, Maddocks K, Buske C, Ambarkhane S, Winderlich M, Dirnberger-Hertweck M, Korolkiewicz R, Blum KA.

Ann Oncol. 2018 May 1;29(5):1266-1272. doi: 10.1093/annonc/mdy056.

12.

Prognostic value of quantitative ctDNA levels in non small cell lung cancer patients.

Provencio M, Torrente M, Calvo V, Pérez-Callejo D, Gutiérrez L, Franco F, Pérez-Barrios C, Barquín M, Royuela A, García-García F, Bueno C, Garcia-Grande A, Camps C, Massuti B, Sotomayor E, Romero A.

Oncotarget. 2017 Nov 16;9(1):488-494. doi: 10.18632/oncotarget.22470. eCollection 2018 Jan 2.

13.

Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain.

Arriola E, García Gómez R, Diz P, Majem M, Martínez Aguillo M, Valdivia J, Paredes A, Sánchez-Torres JM, Peralta Muñoz S, Barneto I, Gutierrez V, Andrade Santiago JM, Aparisi F, Isla D, Ponce S, Vicente Baz D, Artal A, Amador M, Provencio M.

BMC Cancer. 2018 Jan 30;18(1):106. doi: 10.1186/s12885-018-4004-7.

14.

Analysis of the mutational landscape of classic Hodgkin lymphoma identifies disease heterogeneity and potential therapeutic targets.

Mata E, Díaz-López A, Martín-Moreno AM, Sánchez-Beato M, Varela I, Mestre MJ, Santonja C, Burgos F, Menárguez J, Estévez M, Provencio M, Sánchez-Espiridión B, Díaz E, Montalbán C, Piris MA, García JF.

Oncotarget. 2017 Nov 30;8(67):111386-111395. doi: 10.18632/oncotarget.22799. eCollection 2017 Dec 19.

15.

Mutational profile of primary breast diffuse large B-cell lymphoma.

Franco F, González-Rincón J, Lavernia J, García JF, Martín P, Bellas C, Piris MA, Pedrosa L, Miramón J, Gómez-Codina J, Rodríguez-Abreu D, Machado I, Illueca C, Alfaro J, Provencio M, Sánchez-Beato M.

Oncotarget. 2017 Oct 24;8(61):102888-102897. doi: 10.18632/oncotarget.21986. eCollection 2017 Nov 28.

16.

Twice-daily chemoradiotherapy must still be the choice for patients with limited-stage small-cell lung cancer.

Franco F, Pérez-Callejo D, Provencio M.

J Thorac Dis. 2017 Sep;9(9):2843-2846. doi: 10.21037/jtd.2017.08.113. No abstract available.

17.

PGC-1alpha levels correlate with survival in patients with stage III NSCLC and may define a new biomarker to metabolism-targeted therapy.

Cruz-Bermúdez A, Vicente-Blanco RJ, Laza-Briviesca R, García-Grande A, Laine-Menéndez S, Gutiérrez L, Calvo V, Romero A, Martín-Acosta P, García JM, Provencio M.

Sci Rep. 2017 Nov 30;7(1):16661. doi: 10.1038/s41598-017-17009-6.

18.

Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial.

Abad A, Martínez-Balibrea E, Viéitez JM, Alonso-Orduña V, García Alfonso P, Manzano JL, Massutí B, Benavides M, Carrato A, Zanui M, Gallego J, Grávalos C, Conde V, Provencio M, Valladares-Ayerbes M, Salazar R, Sastre J, Montagut C, Rivera F, Aranda E.

Ann Oncol. 2018 Feb 1;29(2):439-444. doi: 10.1093/annonc/mdx737.

PMID:
29145602
19.

Alcohol consumption and lung cancer risk in never smokers: a pooled analysis of case-control studies.

García Lavandeira JA, Ruano-Ravina A, Kelsey KT, Torres-Durán M, Parente-Lamelas I, Leiro-Fernández V, Zapata M, Abal-Arca J, Vidal-García I, Montero-Martínez C, Amenedo M, Castro-Añón O, Golpe-Gómez A, Guzmán-Taveras R, Martínez C, Provencio M, Mejuto-Martí MJ, García-García S, Fernández-Villar A, Piñeiro M, Barros-Dios JM.

Eur J Public Health. 2018 Jun 1;28(3):521-527. doi: 10.1093/eurpub/ckx196.

PMID:
29140412
20.

Environmental tobacco smoke exposure and EGFR and ALK alterations in never smokers' lung cancer. Results from the LCRINS study.

Torres-Durán M, Ruano-Ravina A, Kelsey KT, Parente-Lamelas I, Leiro-Fernández V, Abdulkader I, Provencio M, Abal-Arca J, Castro-Añón O, Montero-Martínez C, Vidal-García I, Amenedo M, Golpe-Gómez A, Martínez C, Guzmán-Taveras R, Mejuto-Martí MJ, Fernández-Villar A, Barros-Dios JM.

Cancer Lett. 2017 Dec 28;411:130-135. doi: 10.1016/j.canlet.2017.09.042. Epub 2017 Oct 5.

PMID:
28987389

Supplemental Content

Loading ...
Support Center